drugset
drugset / Trial / NCT04761627

A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT04761627 ↗

Phase 3 Completed 494 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.

Timeline

Start
2021-03-24
Primary completion
2023-02-28
Completion
2023-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject ABP 654 Protein / enzyme biologic — Subcutaneous
Subject Ustekinumab Monoclonal antibody — Subcutaneous

Indications

psoriasis